A RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTRE, PHASE III STUDYCOMPARING THE EFFICACY AND TOLERABILITY OF FULVESTRANT (FASLODEX?) 500 MG WITH FULVESTRANT (FASLODEX?) 250 MG IN POSTMENOPAUSAL WOMEN WITH OESTROGEN RECEPTOR POSITIVE ADVANCED BREAST CANCER PROGRESSING OR RELAPSING AFTER PREVIOUS ENDOCRINE THERAPY

Phase 1

Active, not recruiting

• Conditions: ADVANCED BREAST CANCER PROGRESSING OR RELAPSING AFTER PREVIOUS ENDOCRINE THERAPY; MedDRA version: 14.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2004-002371-16-IT
• Lead Sponsor: ASTRAZENECA

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-03-15
• Last Update Posted: 2024-01-08

Recruitment & Eligibility

• Status: Not Recruiting
• Sex: Female
• Target Recruitment: 720

Inclusion Criteria

Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: ;Secondary Objective: ;Primary end point(s):